HEALWELL AI INC A SUB VTG - HWAIF STOCK NEWS

HEALWELL AI announced its participation in leading-edge research on Chronic Kidney Disease (CKD). Their Clinical Co-Pilot technology, integrated with a machine model for CKD progression, enhances guideline-recommended testing when paired with EHR-linked clinical decision support. An abstract co-authored by HEALWELL's subsidiary, Khure Health, was published in the American Journal of Kidney Diseases. The research highlights the utility of HEALWELL’s AI technology in improving CKD patient care. CKD is a significant health issue, affecting one-seventh of the North American population and costing Canada over $40 billion annually. Recently, WELL Health Technologies launched its second-generation AI Co-Pilot, powered by HEALWELL, now available to thousands of providers.

HEALWELL AI reported significant growth in Q1-2024, with revenue from continuing operations reaching $4.58 million, a 132% increase compared to $1.97 million in Q1-2023.

This growth is primarily attributed to the acquisition of Intrahealth on February 1, 2024. The company’s revenue run-rate has more than doubled to over $20 million, with SaaS and services forming the largest component.

The management projects potential to more than double the annual revenue to over $40 million with existing cash reserves. HEALWELL closed Q1-2024 with $11.3 million in cash, and an additional $20 million financing deal is expected to further strengthen its financial position.

Despite positive revenue growth, the company posted an adjusted EBITDA loss of $2.56 million. HEALWELL’s strategic alliance with WELL Health Technologies continues to flourish with new AI-driven tools for chronic disease detection.

HEALWELL AI Inc. will announce its Fiscal First Quarter 2024 financial results on May 14, 2024. The company focuses on preventative care and will hold a conference call and webcast to discuss the results, hosted by CEO Dr. Alexander Dobranowski and CFO Scott Nirenberski.

WELL and HEALWELL AI have launched the second-generation WELL AI Decision Support (WAIDS) with advanced chronic disease screening capabilities, aiding in patient risk stratification. The tool identifies over 100 diseases, providing actionable insights at the point of care. Chronic diseases affect 45.1% of Canadians, costing the economy $190 billion annually.

HEALWELL AI Inc. announces its subsidiaries, Khure Health & Pentavere Research Group, will present at major medical conferences in May 2024. Khure Health will showcase AI clinical decision support technology at the National Kidney Foundation Spring Clinical Meetings, while Pentavere will present AI research at various conferences. The conferences include the Canadian Retina Society Annual Meeting, American Head & Neck Society Annual Meeting, and American Medical Informatics Association Clinical Informatics Conference.

Nvidia's focus on healthcare and AI showcases market interest in the intersection of these fields. HEALWELL AI Inc. (HWAIF) emerges as a key player in AI-driven preventative care solutions, with a revenue of $2.8 million in Q3-2023. Recent commercial agreements with WELL Health USA and Circle Medical signal significant growth opportunities for HEALWELL in the U.S. market.

HEALWELL AI Inc. announces a significant milestone with the publication of a peer-reviewed paper by its subsidiary Pentavere Research Group, validating the use of generative AI to identify rare lung cancer patients. This achievement showcases HEALWELL's leadership in developing AI technology applications in healthcare, supporting precision oncology efforts. The paper highlights the successful extraction of a large population cohort of advanced rare EGFRexon20 lung cancer patients for Real World Evidence, providing valuable insights into unmet patient needs and more effective cancer treatments.

HEALWELL AI Inc. announces CEO participation in upcoming investor conferences, including LD Micro Invitational XIV, Bloom Burton & Co. Healthcare Investor Conference, and Planet MicroCap Showcase: VEGAS 2024.

HEALWELL AI Inc. achieved annual revenue of $7.32 million in fiscal 2023, doubling its revenue run rate since Q4 2023 to over $20 million. The company's strategic alliance with WELL Health Technologies Inc. is thriving, leading to significant activities in Canada and the US. HEALWELL's financial results indicate growth potential with a positive outlook for doubling its revenue run-rate to over $40 million. The recent acquisitions and partnerships are positioning HEALWELL as a key player in AI and data science for healthcare.